Sterner et al. have demonstrated that the GM-CSF neutralizing antibody lenzilumab can enhance the anti-tumor activity of CAR-T cells and significantly reduce the severity of CRS and neuroinflammation (NI) in patients with acute lymphoblastic leukemia (ALL) treated with CAR-T cells targeting CD19 [136]. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.